title: HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1.
abstract: BACKGROUND
  Of the cancers treated with allogeneic hematopoietic stem-cell transplantation (HSCT), acute myeloid leukemia (AML) is most sensitive to natural killer (NK)-cell reactivity. The activating killer-cell immunoglobulin-like receptor (KIR) 2DS1 has ligand specificity for HLA-C2 antigens and activates NK cells in an HLA-dependent manner. Donor-derived NK reactivity controlled by KIR2DS1 and HLA could have beneficial effects in patients with AML who undergo allogeneic HSCT.
  
  
  METHODS
  We assessed clinical data, HLA genotyping results, and donor cell lines or genomic DNA for 1277 patients with AML who had received hematopoietic stem-cell transplants from unrelated donors matched for HLA-A, B, C, DR, and DQ or with a single mismatch. We performed donor KIR genotyping and evaluated the clinical effect of donor KIR genotype and donor and recipient HLA genotypes.
  
  
  RESULTS
  Patients with AML who received allografts from donors who were positive for KIR2DS1 had a lower rate of relapse than those with allografts from donors who were negative for KIR2DS1 (26.5% vs. 32.5%; hazard ratio, 0.76; 95% confidence interval [CI], 0.61 to 0.96; P=0.02). Of allografts from donors with KIR2DS1, those from donors who were homozygous or heterozygous for HLA-C1 antigens could mediate this antileukemic effect, whereas those from donors who were homozygous for HLA-C2 did not provide any advantage (24.9% with homozygosity or heterozygosity for HLA-C1 vs. 37.3% with homozygosity for HLA-C2; hazard ratio, 0.46; 95% CI, 0.28 to 0.75; P=0.002). Recipients of KIR2DS1-positive allografts mismatched for a single HLA-C locus had a lower relapse rate than recipients of KIR2DS1-negative allografts with a mismatch at the same locus (17.1% vs. 35.6%; hazard ratio, 0.40; 95% CI, 0.20 to 0.78; P=0.007). KIR3DS1, in positive genetic linkage disequilibrium with KIR2DS1, had no effect on leukemia relapse but was associated with decreased mortality (60.1%, vs. 66.9% without KIR3DS1; hazard ratio, 0.83; 95% CI, 0.71 to 0.96; P=0.01).
  
  
  CONCLUSIONS
  Activating KIR genes from donors were associated with distinct outcomes of allogeneic HSCT for AML. Donor KIR2DS1 appeared to provide protection against relapse in an HLA-C-dependent manner, and donor KIR3DS1 was associated with reduced mortality. (Funded by the National Institutes of Health and others.).
authors.affiliation: Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
authors.forename: Jeffrey M
authors.initials: JM
authors.lastname: Venstrom
authors.forename: Gianfranco
authors.initials: G
authors.lastname: Pittari
authors.forename: Ted A
authors.initials: TA
authors.lastname: Gooley
authors.forename: Joseph H
authors.initials: JH
authors.lastname: Chewning
authors.forename: Stephen
authors.initials: S
authors.lastname: Spellman
authors.forename: Michael
authors.initials: M
authors.lastname: Haagenson
authors.forename: Meighan M
authors.initials: MM
authors.lastname: Gallagher
authors.forename: Mari
authors.initials: M
authors.lastname: Malkki
authors.forename: Effie
authors.initials: E
authors.lastname: Petersdorf
authors.forename: Bo
authors.initials: B
authors.lastname: Dupont
authors.forename: Katharine C
authors.initials: KC
authors.lastname: Hsu
mesh_terms: D000368:Aged; D005838:Genotype; D015236:HLA-C Antigens / Q000235:genetics* / Q000378:metabolism; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D053208:Kaplan-Meier Estimate; D007694:Killer Cells, Natural / Q000276:immunology; D015470:Leukemia, Myeloid, Acute / Q000235:genetics / Q000401:mortality / Q000517:prevention & control* / Q000628:therapy; D016016:Proportional Hazards Models; D054340:Receptors, KIR / Q000235:genetics* / Q000502:physiology; D012189:Retrospective Studies; D055502:Secondary Prevention; D014184:Transplantation, Homologous; D061349:Unrelated Donors
chemical_list: D015236:HLA-C Antigens; C496212:KIR2DS1 protein, human; D054340:Receptors, KIR